Monopar Therapeutics (NASDAQ:MNPR) Upgraded at Cantor Fitzgerald

Cantor Fitzgerald upgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a neutral rating to an overweight rating in a research note issued to investors on Thursday, Marketbeat.com reports. The brokerage currently has $119.00 price target on the stock.

A number of other research analysts have also weighed in on the company. Barclays reissued an “overweight” rating and set a $145.00 target price (up from $128.00) on shares of Monopar Therapeutics in a report on Friday, September 11th. HC Wainwright raised their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price objective on shares of Monopar Therapeutics in a research report on Monday, August 17th. BTIG Research lifted their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $122.75.

Monopar Therapeutics Stock Performance

Monopar Therapeutics stock traded down $0.68 during midday trading on Thursday, reaching $72.00. 203,206 shares of the company’s stock were exchanged, compared to its average volume of 145,014. Monopar Therapeutics has a 52 week low of $50.07 and a 52 week high of $124.82. The firm has a market cap of $483.12 million, a price-to-earnings ratio of -29.88 and a beta of 1.62. The stock’s 50-day simple moving average is $82.59 and its 200 day simple moving average is $77.41.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.72). Research analysts forecast that Monopar Therapeutics will post -2.98 earnings per share for the current year.

Insider Transactions at Monopar Therapeutics

In related news, Director Kim R. Tsuchimoto sold 4,090 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $111.39, for a total value of $455,585.10. Following the completion of the sale, the director directly owned 7,396 shares in the company, valued at $823,840.44. The trade was a 35.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chandler Robinson sold 29,056 shares of the company’s stock in a transaction on Thursday, September 24th. The shares were sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer directly owned 99,267 shares in the company, valued at approximately $8,735,496. This represents a 22.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 51,920 shares of company stock worth $4,527,913 over the last three months. Company insiders own 9.70% of the company’s stock.

Institutional Investors Weigh In On Monopar Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in shares of Monopar Therapeutics in the 2nd quarter valued at $7,124,000. Walleye Capital LLC bought a new position in shares of Monopar Therapeutics in the 1st quarter valued at $3,458,000. Siren L.L.C. raised its holdings in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock worth $14,800,000 after buying an additional 57,820 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after buying an additional 53,336 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Monopar Therapeutics by 24.1% during the 3rd quarter. State Street Corp now owns 229,771 shares of the company’s stock worth $18,306,000 after buying an additional 44,669 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

Latest Monopar Therapeutics News

These are some of the MNPR news items that stood out recently:

• Positive Sentiment: Cantor Fitzgerald upgraded MNPR from “Neutral” to “Overweight” and set a $119 price target, implying substantial upside from the cited $72 share price. Cantor Fitzgerald rating article
• Positive Sentiment: Monopar reported third-quarter 2026 EPS of a $0.72 loss, better than analysts’ consensus estimate of a $0.82 loss. The company also released quarterly results and business updates. Third-quarter results and business updates
• Neutral Sentiment: HC Wainwright maintained its “Buy” rating and issued 2027 quarterly EPS estimates ranging from a $0.91 to a $1.19 loss per share. The projections indicate continued expected losses, but no change in rating was reported.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its pipeline includes radiopharmaceutical candidates designed to target the urokinase plasminogen activator receptor (uPAR), a protein found at elevated levels in some cancers. The company is developing MNPR-101-Zr as an imaging agent to identify uPAR-expressing tumors and MNPR-101-Lu as a potential targeted radiation therapy. These candidates are investigational and are not approved for commercial use.